Gilead Sciences, Inc.
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 3, 2026), Gilead Sciences, Inc. reported 5 stock positions worth $1.6 billion. Its top holding was Arcus Biosciences (RCUS) at 58.8% of the portfolio, followed by Lakefront Biotherapeutic-ADR (LKFT, 30.3%) and Assembly Biosciences (ASMB, 8.3%). Compared with Q1 2026, it sold out of 1 and added to 1. The biggest buy was Assembly Biosciences (ASMB, shares +10%) and the biggest sale an exit from Arcellx (ACLX).
- Most Recent 13F
- Q2 2026
- Location
- FOSTER CITY, CA
- CIK
- 0000882095
- Portfolio Value
- $1.6B (Q2 2026)
- SEC Filing
- 0001123292-26-001034 ↗ filed Aug 3, 2026
Holdings Value
Holdings 5 stocks · $1.6B
| RCUS Arcus Biosciences Inc. | 58.76% | 31,424,760 | $968.8M | No change |
| LKFT Lakefront Biotherapeutic-ADR | 30.34% | 16,707,477 | $500.2M | No change |
| ASMB Assembly Biosciences Inc. | 8.30% | 4,977,089 | $136.8M | Add +10.5% |
| KYTX Kyverna Therapeutics Inc. | 2.23% | 4,126,119 | $36.8M | No change |
| XLO Xilio Therapeutics Inc. | 0.38% | 650,389 | $6.2M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| ACLX Arcellx Inc. | Sold out | 0.00% | −36.44 |
Portfolio Buys Q1 2026 → Q2 2026
| ASMB Assembly Biosciences Inc. | Add +10.5% | 8.30% | +2.39 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.6B | RCUS, LKFT, ASMB, KYTX, XLO |
| Q1 2026 | 6 | $2.1B | ACLX, RCUS, LKFT, ASMB, KYTX |
| Q4 2025 | 6 | $1.9B | RCUS, LKFT, ACLX, ASMB, KYTX |
| Q3 2025 | 9 | $1.8B | LKFT, ACLX, RCUS, ASMB, MRUS |
| Q2 2025 | 14 | $1.3B | LKFT, ACLX, RCUS, ASMB, TNGX |
| Q1 2025 | 14 | $1.2B | ACLX, LKFT, RCUS, ASMB, MRUS |
| Q4 2024 | 16 | $1.6B | ACLX, LKFT, RCUS, ASMB, MRUS |